Müller Arndt-Christian, Eckert Franziska, Paulsen Frank, Zips Daniel, Stenzl Arnulf, Schilling David, Alber Markus, Bares Roland, Martus Peter, Weckermann Dorothea, Belka Claus, Ganswindt Ute
Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany.
Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany.
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):263-71. doi: 10.1016/j.ijrobp.2015.10.031. Epub 2015 Dec 10.
To assess the efficacy of individual sentinel node (SN)-guided pelvic intensity modulated radiation therapy (IMRT) by determining nodal clearance rate [(n expected nodal involvement - n observed regional recurrences)/n expected nodal involvement] in comparison with surgically staged patients.
Data on 475 high-risk prostate cancer patients were examined. Sixty-one consecutive patients received pelvic SN-based IMRT (5 × 1.8 Gy/wk to 50.4 Gy [pelvic nodes + individual SN] and an integrated boost with 5 × 2.0 Gy/wk to 70.0 Gy to prostate + [base of] seminal vesicles) and neo-/adjuvant long-term androgen deprivation therapy; 414 patients after SN-pelvic lymph node dissection were used to calculate the expected nodal involvement rate for the radiation therapy sample. Biochemical control and overall survival were estimated for the SN-IMRT patients using the Kaplan-Meier method. The expected frequency of nodal involvement in the radiation therapy group was estimated by imputing frequencies of node-positive patients in the surgical sample to the pattern of Gleason, prostate-specific antigen, and T category in the radiation therapy sample.
After a median follow-up of 61 months, 5-year OS after SN-guided IMRT reached 84.4%. Biochemical control according to the Phoenix definition was 73.8%. The nodal clearance rate of SN-IMRT reached 94%. Retrospective follow-up evaluation is the main limitation.
Radiation treatment of pelvic nodes individualized by inclusion of SNs is an effective regional treatment modality in high-risk prostate cancer patients. The pattern of relapse indicates that the SN-based target volume concept correctly covers individual pelvic nodes. Thus, this SN-based approach justifies further evaluation, including current dose-escalation strategies to the prostate in a larger prospective series.
通过确定淋巴结清除率[(预期淋巴结受累数-观察到的区域复发数)/预期淋巴结受累数],评估个体化前哨淋巴结(SN)引导的盆腔调强放射治疗(IMRT)与手术分期患者相比的疗效。
检查了475例高危前列腺癌患者的数据。61例连续患者接受了基于盆腔SN的IMRT(5×1.8 Gy/周,共50.4 Gy[盆腔淋巴结+个体化SN],并以5×2.0 Gy/周的剂量进行综合增敏至70.0 Gy,照射前列腺+精囊[底部])以及新辅助/辅助长期雄激素剥夺治疗;414例接受SN-盆腔淋巴结清扫的患者用于计算放疗样本的预期淋巴结受累率。采用Kaplan-Meier法评估SN-IMRT患者的生化控制和总生存率。通过将手术样本中淋巴结阳性患者的频率代入放疗样本中的Gleason分级、前列腺特异性抗原和T分期模式,估计放疗组淋巴结受累的预期频率。
中位随访61个月后,SN引导的IMRT后的5年总生存率达到84.4%。根据Phoenix定义的生化控制率为73.8%。SN-IMRT的淋巴结清除率达到94%。回顾性随访评估是主要局限性。
纳入SN个体化的盆腔淋巴结放射治疗是高危前列腺癌患者有效的区域治疗方式。复发模式表明基于SN的靶区体积概念正确覆盖了个体盆腔淋巴结。因此,这种基于SN的方法值得进一步评估,包括在更大的前瞻性系列中对前列腺目前的剂量递增策略进行评估。